Resultados de procura - Gideon Bollag

Limitar resultados
  1. 1
    Characterization of full-length neurofibromin: tubulin inhibits Ras GAP activity.

    Characterization of full-length neurofibromin: tubulin inhibits Ras GAP activity. por Gideon Bollag, Frank McCormick, R Clark

    Publicado 1993
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    Discovery of a novel Raf kinase inhibitor.

    Discovery of a novel Raf kinase inhibitor. por John F. Lyons, S M Wilhelm, Barbara Hibner, Gideon Bollag

    Publicado 2001
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  3. 3
    A novel serine kinase activated by rac1/CDC42Hs-dependent autophosphorylation is related to PAK65 and STE20.

    A novel serine kinase activated by rac1/CDC42Hs-dependent autophosphorylation is related to PAK65 and STE20. por George A. Martin, Gideon Bollag, Frank McCormick, Arie Abo

    Publicado 1995
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

    RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF por Poulikos I. Poulikakos, Chao Zhang, Gideon Bollag, Kevan M. Shokat, Neal Rosen

    Publicado 2010
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Protein kinase C directly phosphorylates the insulin receptor in vitro and reduces its protein-tyrosine kinase activity.

    Protein kinase C directly phosphorylates the insulin receptor in vitro and reduces its protein-tyrosine kinase activity. por Gideon Bollag, Richard A. Roth, Jacqueline Beaudoin, Daria Mochly‐Rosen, D E Koshland

    Publicado 1986
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Identification of a Novel Guanine Nucleotide Exchange Factor for the Rho GTPase

    Identification of a Novel Guanine Nucleotide Exchange Factor for the Rho GTPase por Matthew J. Hart, Sanju Sharma, Nadia elMasry, Rong-Guo Qiu, Peter C. McCabe, Paul Polakis, Gideon Bollag

    Publicado 1996
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition

    Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition por Stephen Mok, Jennifer Tsoi, Richard C. Koya, Siwen Hu‐Lieskovan, Brian L. West, Gideon Bollag, Thomas G. Graeber, Antoni Ribas

    Publicado 2015
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    Biochemical and Functional Characterization of Germ Line <i>KRAS</i> Mutations

    Biochemical and Functional Characterization of Germ Line <i>KRAS</i> Mutations por Suzanne Schubbert, Gideon Bollag, Natalya Lyubynska, Hoa Nguyen, Christian P. Kratz, Martin Zenker, Charlotte M. Niemeyer, Anders Molven, Kevin Shannon

    Publicado 2007
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in<i>BRAF</i>Mutant Thyroid Carcinoma Cells

    Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in<i>BRAF</i>Mutant Thyroid Carcinoma Cells por Paolo Salerno, Valentina De Falco, Anna Tamburrino, Tito Claudio Nappi, Giancarlo Vecchio, Rebecca E. Schweppe, Gideon Bollag, Massimo Santoro, Giuliana Salvatore

    Publicado 2009
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT–dependent apoptosis in diffuse large B-cell lymphoma

    The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT–dependent apoptosis in diffuse large B-cell lymphoma por Peter G. Smith, Fengfei Wang, Kathryn Wilkinson, Kerry J. Savage, Ulf Klein, Donna Neuberg, Gideon Bollag, Margaret A. Shipp, Ricardo C.T. Aguiar

    Publicado 2004
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer

    CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer por Jingying Xu, Jemima Escamilla, Stephen Mok, John David, Saul J. Priceman, Brian L. West, Gideon Bollag, William H. McBride, Lily Wu

    Publicado 2013
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  12. 12
    Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice

    Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice por Cédric Louvet, Gregory L. Szot, Jiena Lang, Michael R. F. Lee, Nicolas Martinier, Gideon Bollag, Shirley Zhu, Arthur J. Weiss, Jeffrey A. Bluestone

    Publicado 2008
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy

    Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy por Stephen Mok, Richard C. Koya, Christopher Tsui, Jingying Xu, Lídia Robert, Lily Wu, Thomas G. Graeber, Brian L. West, Gideon Bollag, Antoni Ribas

    Publicado 2013
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase <i>BRAF</i> -mutant lung cancer

    Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase <i>BRAF</i> -mutant lung cancer por Ross A. Okimoto, Luping Lin, Victor Olivas, Elton Chan, Evan Markegard, Andrey Rymar, Dana S. Neel, Xiaohong Chen, Golzar Hemmati, Gideon Bollag, Trever G. Bivona

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer

    Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer por Carmelo Nucera, Matthew A. Nehs, Sushruta S. Nagarkatti, Peter M. Sadow, Michal Mekel, Andrew H. Fischer, Paul Lin, Gideon Bollag, Jack Lawler, Richard A. Hodin, Sareh Parangi

    Publicado 2011
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas

    PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas por John Tayu Lee, Ling Li, Patricia Brafford, Marcia van den Eijnden, Molly B. Halloran, Katrin Sproesser, Nikolas K. Haass, Keiran S.M. Smalley, James Tsai, Gideon Bollag, Meenhard Herlyn

    Publicado 2010
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  17. 17
    Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

    Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer por Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, William D. Bradley, Richard J. Lee, Kathleen Schostack, Mary Ellen Simcox, Scott Kopetz, David Heimbrook, Brian Lestini, Gideon Bollag, Fei Su

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  18. 18
    Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma

    Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma por William D. Tap, Ke-Wei Gong, Judy Daring, Yiou Tseng, Charles Ginther, Giovanni M. Pauletti, John A. Glaspy, Richard Essner, Gideon Bollag, Peter Hirth, Chao Zhang, Dennis J. Slamon

    Publicado 2010
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  19. 19
    BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model

    BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model por Daniele Perna, Florian A. Karreth, Alistair G. Rust, Pedro A. Pérez–Mancera, Mamunur Rashid, Francesco Iorio, Constantine Alifrangis, Mark J. Arends, Marcus Bosenberg, Gideon Bollag, David A. Tuveson, David J. Adams

    Publicado 2015
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  20. 20
    Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition

    Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition por Carlos E. Prada, Edwin Jousma, Tilat A. Rizvi, Jianqiang Wu, R. Scott Dunn, Debra A. Mayes, José A. Cancelas, Eva Dombi, Mi‐Ok Kim, Brian L. West, Gideon Bollag, Nancy Ratner

    Publicado 2012
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: